Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012

This Letter describes the continued optimization of an MLPCN probe molecule M(1) antagonist (ML012) through an iterative parallel synthesis approach. After several rounds of modifications of the parent compound, we arrived at a new azetidine scaffold that displayed improved potency while maintaining...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Melancon, Bruce J., Utley, Thomas J., Sevel, Christian, Mattmann, Margrith E., Cheung, Yiu-Yin, Bridges, Thomas M., Morrison, Ryan D., Sheffler, Douglas J., Niswender, Colleen M., Daniels, J. Scott, Conn, P. Jeffrey, Lindsley, Craig W., Wood, Michael R.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2012
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3883446/
https://ncbi.nlm.nih.gov/pubmed/22749871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bmcl.2012.06.018
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller